Statistics for Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
Total visits
| views | |
|---|---|
| Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) | 3 |
Total visits per month
| views | |
|---|---|
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
File Visits
| views | |
|---|---|
| BJD-184-437.pdf | 4 |
Top country views
| views | |
|---|---|
| United States | 2 |
| India | 1 |
Top city views
| views | |
|---|---|
| Bloomington | 2 |